10th Annual

Fragment-Based Drug Discovery

From Hits to Leads and Lessons Learned

April 22-23, 2015 

 
 

A mutli-disciplinary gathering where you can gain new insights and refresh on new ideas
through networking and presentations

Djamal B., Arisan Therapeutics

Fragment-based approaches to find new small molecule drug candidates are now part of most drug discovery campaigns. This was not the case less than a decade ago. However with at least one drug on the market and more than twenty in clinical development whose origins can be traced to fragment-based screens, understanding the role and limitations of fragment-based drug design in order to capitalize on its promise and make it an efficient and seamless part of drug discovery is becoming more important than ever.

The challenge of fragment-based drug design campaigns has always been progressing fragment hits against the target compound to obtaining a clinical candidate. Via case studies on success stories and compounds moving forward or not in preclinical development, join fellow biophysical and medicinal chemists at Cambridge Healthtech Institute's Fragment-Based Drug Discovery to learn about best practices and pitfalls to avoid. This day-and-a-half meeting is in the second half of CHI’s larger Drug Discovery Chemistry event.

Topics may include, but are not limited to: 

  • New concepts in library design (3D advantages, Diversity-Oriented Screening, pros and cons of general vs specialized fragment libraries)
  • Importance of ligand efficiency
  • Combining and comparing approaches for fragment library screening (SPR, NMR, DSF—differential screening fluorescence)
  • Defragmentation –using compounds from HTS screens, breaking them into fragments to find which parts have the highest affinity and building-out from there
  • Adding value to other screening protocols/integrating with HTS
  • Beyond kinases: finding fragments against PPIs and membrane proteins
  • Case studies of drug candidates arising from fragment-based screening campaigns

If you would like to submit a proposal to give a presentation at this meeting, please click here.

The deadline for submission is September 29, 2014 

All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program.  Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships. 

For more details on the conference, please contact:
Anjani Shah, Ph.D.
Conference Director
Cambridge Healthtech Institute
Phone: (914) 723-0255
Email: ashah@healthtech.com 

For partnering and sponsorship information, please contact:
Carolyn Benton
Business Development Manager
Cambridge Healthtech Institute
Phone: (+1) 781-972-5412
Email: cbenton@healthtech.com